Stereotactic ablative radiotherapy (SABR) for patients with lung tumor and severe pulmonary function impairment

• Abraham André Arturo Geng Cahuayme ^[1] ; Blanca Peregrín Pastor ^[1] ; Mónica Ramos Albiac ^[1] ; Enar Recalde Vizcay ^[1] ; Juan Sebastián Parada Zuluaga ^[1] ; Jordi Giralt López de Sagredo ^[1] ; Xavier Maldonado Pijoan ^[1] ; Alexandra Giraldo Marín ^[1]
  1. [1] Department of Radiation Oncology, Vall d’Hebron University Hospital, Passeig de la Vall d’Hebron 119, 08035 Barcelona, Spain
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 12, 2024, págs. 3246-3251
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To evaluate clinical outcomes after SABR in a cohort of early-stage non-small cell lung cancer (NSCLC) or pulmonary metastases in chronic obstructive pulmonary disease (COPD) patients with forced expiratory volume in the frst second predicted (FEV1)≤50%.

    Methods Retrospective single-center study was performed to analyze clinical outcomes and toxicities in COPD patients with severe lung dysfunction treated with SABR from 1st June 2015 to 31st October 2022.

    Results Thirty four patients (forty locations) were enrolled for analysis. Median follow-up was 2.9 years. Median age was 73.5 years (range, 65.6–80.1). FEV1 was 38% (range, 28.2–50.0) prior to radiotherapy. Median overall survival (OS) was 41.1 months (95% CI 38.9—not reached). OS rates at 2-, 3-, and 5- years were 79%, 71%, and 36%, respectively. Cancerspecifc survival rates at 2-, 3-, and 5- years were 96%, 96%, and 68%, respectively. Local control rates at 2-, 3-, and 5- years were 88%, 83%, and 83%, respectively. No grade 4 or 5 toxicity was observed. The most common acute toxicity was pneumonitis (38.2%), of which only 1 patient (2.9%) reported grade 3 acute toxicity.

    Conclusions Lung SABR in patients with poor pulmonary function may be efective with acceptable toxicity.